Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan

Phung‐Anh Nguyen,Chih‐Cheng Chang,Cooper J. Galvin,Yao‐Chin Wang,Soo Yeon An,Chih‐Wei Huang,Yu‐Hsiang Wang,Min‐Huei Hsu,Yu‐Chuan Li,Hsuan‐Chia Yang,Yu‐Chuan (Jack) Li
DOI: https://doi.org/10.1111/cas.14493
IF: 5.7
2020-07-06
Cancer Science
Abstract:<p>Statins have shown beneficial treatment as chemotherapy and target‐therapy for lung cancer. This study aims to investigate the effectiveness of statins in combination with epidermal growth factor receptor‐ tyrosine kinase inhibitors (EGFR‐TKIs) therapy on resistance and mortality of lung cancer patients. A population‐based cohort study was conducted using the Taiwan Cancer Registry database. From January 1, 2007, to December 31, 2012, a total of 792 non‐statins and 41 statins users had undergone EGFR‐TKIs treatment and were included in this study. All patients were monitored until the event of death or were changed to another therapy. Kaplan‐Meier estimators and Cox proportional‐hazards regression models were used to computing overall survival. We found that the mortality was significantly lower with statins compared to non‐statins group (4‐year cumulative mortality, 77.3%; 95% CI, 36.6%‐81.4% vs. 85.5%; 95% CI, 78.5%‐98%; p=0.004). Also, statin use was associated with a reduced risk of death in the group that had a tumor size&lt;3 cm (HR, 0.51, 95% CI, 0.29‐0.89) and in the group with CCI‐scores&lt;3 (HR, 0.6; 95% CI, 0.41‐0.88; p=0.009). In our study, statins are associated with prolonged survival time in lung cancers with EGFR‐TKIs and play a synergistic anticancer role.</p>
oncology
What problem does this paper attempt to address?